Sanofi to refocus two global business units19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.
Sanofi will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets.
The company will create a new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU. The new Primary Care unit will focus exclusively on mature markets.
To help build and lead the new Primary Care business, Sanofi is appointing Dieter Weinand as Executive Vice President. Effective 1 November, Mr Weinand will report directly to Sanofi CEO Olivier Brandicourt and become a member of the Executive Committee. He will be based in the Bridgewater, New Jersey, USA. Stefan Oelrich, currently head of the DCV GBU, has decided to leave Sanofi and will join Bayer as a member of the Board of Management and head of the Pharmaceuticals division, replacing Mr. Weinand effective November 1st.
"Dieter is a seasoned professional with significant experience in the pharmaceutical sector, having successfully launched and marketed some of the most innovative medicines in the last few years. He has a proven track record in change management and helping challenged businesses reach their full potential," said Dr Brandicourt. "As we welcome Dieter into the organization, I would like to thank Stefan for his excellent contributions to Sanofi over the years and wish him all the best in his next endeavour."
Sanofi is creating a second new GBU called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU. This newly formed business will focus on the unique characteristics and tremendous growth opportunities in emerging markets, particularly in China, which is Sanofi's second largest market after the US. Mr Charmeil will continue to be a member of the Executive Committee reporting directly to Dr Brandicourt.
Sanofi expects to launch the new Primary Care and China & Emerging Markets global business units by the beginning of 2019. Sanofi's other GBUs - Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare - remain unchanged.
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Brexit's trick or treat on patient safety
29 Apr 2019
Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.Read more
Surge of Indian biosimilars market forecast in 2019
22 Apr 2019
India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.Read more
RAPS on delayed Brexit
26 Mar 2019
The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.Read more
Sizeable growth potential for global drug delivery and packaging in 2019
19 Mar 2019
Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.Read more
'Tamper-evident' benefits are evident
28 Feb 2019
2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.Read more
All Recipharm facilities ready for EU serialisation, regardless of Brexit
15 Feb 2019
The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation